Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

BACKGROUND: In patients with discordance between low‐density lipoprotein (LDL) cholesterol and LDL particle (LDL‐P) concentrations, cardiovascular risk more closely correlates with LDL−P. METHODS AND RESULTS: We investigated the effect of alirocumab, a fully human monoclonal antibody to proprotein c...

Descripción completa

Detalles Bibliográficos
Autores principales: Koren, Michael J., Kereiakes, Dean, Pourfarzib, Ray, Winegar, Deborah, Banerjee, Poulabi, Hamon, Sara, Hanotin, Corinne, McKenney, James M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845239/
https://www.ncbi.nlm.nih.gov/pubmed/26586732
http://dx.doi.org/10.1161/JAHA.115.002224

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4845239/
https://www.ncbi.nlm.nih.gov/pubmed/26586732
http://dx.doi.org/10.1161/JAHA.115.002224

Ejemplares similares